{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"170","value":"2.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"7.0","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.00","upperLimit":"25.0","value":"3.00"},{"groupId":"OG001","lowerLimit":"1.00","upperLimit":"25.0","value":"2.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Cycle 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Includes participants from all treatment arms that were administered AMG 820 1100 mg.","id":"OG000","title":"AMG 820 1100 mg"},{"description":"Includes participants from all treatment arms who were administered AMG 820 1400 mg","id":"OG001","title":"AMG 820 1400 mg"}],"paramType":"MEDIAN","populationDescription":"Pharmacovigilence Analysis Set contains all participants who received at least 1 dose of AMG 820 and have at least one PK sample collected.","reportingStatus":"POSTED","timeFrame":"Cycle 1, Study Day 1: pre-infusion, at end of infusion, hours 1, 6 and 24 post infusion, Days 5, 8 and 15. Cycle 2, Study Day 22: pre-infusion, at end of infusion, hours 1, 6, 24 post infusion, Days 26, 29 and 36","title":"AMG 820 Pharmacokinetic Parameter by Dose Group: Time of Maximum Observed Concentration (Tmax) During Treatment Cycles 1 + 2","type":"SECONDARY","unitOfMeasure":"hour"}